Yongjian Liu, PhD

Research Interest

My research has focused on the development and validation of novel molecular probes from preclinical research to translational PET imaging and therapy. These imaging agents are built upon a number of platforms including peptides, small molecules, antibodies, and nanostructures and are radiolabeled with various radionuclides according to the biological half-life of the biomolecules and decay half-life of the radionuclides. Through the collaboration with other investigators, I have translated four imaging agents for human imaging including 2 radiolabeled antibodies for cancer patients PET imaging, a targeted nanoparticle for human atherosclerosis and a CCR2 targeted ECLi1 peptide for human inflammation imaging.

Education

• 2000: MS, environmental science, Zhejiang University, Hangzhou, Zhejiang, China
• 2007: PhD, radiochemistry, University of Missouri, Columbia

Training

• 2007 - 2011: Postdoctoral fellow, Washington University, St. Louis